Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

Barbara Rossetti, Roberta Gagliardini, Genny Meini, Gaetana Sterrantino, Vincenzo Colangeli, Maria Carla Re, Alessandra Latini, Manuela Colafigli, Francesca Vignale, Stefano Rusconi, Valeria Micheli, Antonio Di Biagio, Giancarlo Orofino, Valeria Ghisetti, Alessandra Fantauzzi, Vincenzo Vullo, Pierfrancesco Grima, Daniela Francisci, Claudio Mastroianni, Andrea Antinori, Michele Trezzi, Lucia Lisi, Pierluigi Navarra, Benedetta Canovari, Antonella D’Arminio Monforte, Silvia Lamonica, Alessandro D’Avino, Maurizio Zazzi, Simona Di Giambenedetto, Andrea De Luca and for GUSTA trial study Group

PLOS ONE, 2017, vol. 12, issue 11, 1-18

Abstract: Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA

Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187393 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 87393&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0187393

DOI: 10.1371/journal.pone.0187393

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().